Comparative Pharmacology
Head-to-head clinical analysis: ECOZA versus NIZORAL ANTI DANDRUFF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ECOZA versus NIZORAL ANTI DANDRUFF.
ECOZA vs NIZORAL ANTI-DANDRUFF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Ketoconazole, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase (CYP51), preventing the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes. This disrupts membrane integrity and function.
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
Apply to wet hair, lather, and leave on for 3-5 minutes before rinsing. Use twice weekly for 4 weeks, then as needed to control dandruff.
None Documented
None Documented
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal elimination half-life is biphasic: initial 2 hours, terminal 8 hours (range 6-10 hours). After topical application, systemic absorption is minimal, resulting in an effective half-life of 72-96 hours in skin.
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Primarily fecal (57%) via biliary excretion as unchanged drug and metabolites; renal excretion accounts for approximately 13% (2-4% unchanged).
Category C
Category C
Topical Antifungal
Topical Antifungal